1. 0
    FDA and SEC Open a New Information-Sharing Channel: Implications for Public Life Sciences Companies governance corpgov.law.harvard.edu
    via editorial

Key Takeaways: The U.S. Food and Drug Administration and Securities and Exchange Commission recently announced a new three-year Memorandum of Understanding (“MOU”) establishing a formal framework for the agencies to exchange nonpublic information concerning FDA-regulated products, activities and companies. For pharmaceutical, biotechnology and medical-device companies that are publicly traded or otherwise are SEC-reporting companies, the […]

Source: Harvard Law School Forum on Corporate Governance

Published: 2026-09-22T11:30:43Z